PMC:7195088 / 32953-33270 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T41","span":{"begin":52,"end":56},"obj":"Body_part"},{"id":"T42","span":{"begin":52,"end":54},"obj":"Body_part"}],"attributes":[{"id":"A41","pred":"fma_id","subj":"T41","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A42","pred":"fma_id","subj":"T42","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T170","span":{"begin":190,"end":198},"obj":"Disease"}],"attributes":[{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T185","span":{"begin":205,"end":210},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T444","span":{"begin":14,"end":25},"obj":"Chemical"},{"id":"T445","span":{"begin":52,"end":54},"obj":"Chemical"},{"id":"T447","span":{"begin":66,"end":76},"obj":"Chemical"},{"id":"T448","span":{"begin":140,"end":151},"obj":"Chemical"},{"id":"T449","span":{"begin":205,"end":210},"obj":"Chemical"}],"attributes":[{"id":"A444","pred":"chebi_id","subj":"T444","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A445","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A446","pred":"chebi_id","subj":"T445","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A447","pred":"chebi_id","subj":"T447","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A448","pred":"chebi_id","subj":"T448","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A449","pred":"chebi_id","subj":"T449","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T265","span":{"begin":200,"end":249},"obj":"Sentence"},{"id":"T266","span":{"begin":250,"end":317},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of tocilizumab vs. anakinra (recombinant IL-1 receptor antagonist) vs. siltuximab vs. anakinra plus siltuximab vs. anakinra plus tocilizumab vs. standard of care in patients with COVID-19. Open-label RCT (NCT04330638, not yet recruiting). Primary endpoint: time to clinical improvement (follow-up 15 days)."}